Journal
PLANT MOLECULAR BIOLOGY
Volume 57, Issue 1, Pages 101-113Publisher
SPRINGER
DOI: 10.1007/s11103-004-6832-x
Keywords
Gaucher disease; human acid beta-glucosidase; pharmaceutical proteins; seed-specific expression; transgenic plants
Categories
Ask authors/readers for more resources
Gaucher disease, the most common genetic lysosomal disorder, is caused by the lack of functional acid beta-glucosidase (GCase) and is currently treated at a very high cost by enzyme replacement therapy. In an attempt to provide a safe and cost-effective production system, human placental GCase was produced and purified from transgenic tobacco seeds. Plant-derived recombinant GCase was found to be enzymatically active, uptaken by human fibroblasts and free of immunogenic xylose and fucose residues. This report demonstrates the potential of plant bioreactors in the large-scale production of injectable proteins required for lifelong therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available